| abstract |
Disclosed are compositions for eliciting anti-SARS-CoV-2 immune responses in subjects. In some embodiments, the compositions include one or more SARS-CoV-2 antigens and one or more PEGylated liposomal adjuvants, wherein at least one of the PEGylated liposomal adjuvants includes a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid. Also provided are methods for using the presently disclosed compositions for stimulating anti-SARS-CoV-2 immune responses, for inducing anti- SARS-CoV-2 Thl responses, for stimulating systemic immune responses and/or mucosal immune responses, for inducing anti-SARS-CoV-2 IgA responses, for reducing SARS- CoV-2-induced lung injuries, and for inducing anti-SARS-CoV-2 neutralizing antibodies in subjects in need thereof. |